1 / 2

Assessment of the primary endpoint at 1 year (minimal FU of 6 months for the last patients)

A ssessment with a double R andomization of 1) a monitoring-adjusted antiplatelet treatment vs. a C ommon antiplatelet T reatment for DES implantation, and 2) I nterruption vs. C ontinuation of double antiplatelet therapy one year after stenting.

nitza
Download Presentation

Assessment of the primary endpoint at 1 year (minimal FU of 6 months for the last patients)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Assessment with a double Randomization of 1) a monitoring-adjusted antiplatelet treatment vs. a Common antiplatelet Treatment for DES implantation, and 2) Interruption vs. Continuation of double antiplatelet therapy one year after stenting Randomisation beforeplanned PCI with DES (n=2500) • Monitoring Treatment Arm • -Systematicassessment of the pharmacodynamic response to clopidogrel and aspirinbefore DES placement and between D14-D30. • 2-Adjustment of APT* dose regimen if high-on treatmentplateletreactivitybefore DES placement** • 3-Adjustment of APT* dose regimen if high-on treatmentplateletreactivityduring the maintenance phase (@ d14-30 )** • Conventionnal Arm • - No monitoring of pharmacodynamic plateletresponse • - APT* strategyisleftat the physiciandiscretionaccording to routine practice • Assessment of the primary endpoint at 1 year (minimal FU of 6 months for the last patients) • All Cause Mortality • Myocardial Infarction • All Urgent Revascularization • Stent Thrombosis requiring revascularization or not • Ischemic Stroke requiring a new hospitalization *APT = Antiplatelet Therapy; **In the absence of high-on treatmentplateletreactivity: DAPT dose regimenis 75mg of aspirin and 75mg of clopidogrel

  2. Planned PCI with DES, pretreated with aspirin and clopidogrel/prasugrel (local practice) and randomized to the Monitoring Treatment Arm VerifyNowbefore PCI : Aspirin & P2Y12 Thienopyridine %inh<15% /PRU>235 (P2Y12cartridge) ARU>550 (Aspirin cartridge) Reload with 500 mg of IV aspirin GPIIb/IIIainh. + clopidogrel (re)-loading (>or=600 mg) or prasugrel 60 mg and maintenance dose of 150 mg or prasugrel 10mg* VerifyNow @ day 14-30 Aspirin & P2Y12 thienopyridine for all patients • %inh>90% ARU>550 • %inh<15%/PRU>235 if clopidogrel 150mg, ↘ to 75mg or if on prasugrel switch to clopidogrel 75mg ↗Clopidogrel dose by at least 75 mg or switch to prasugrel 10mg* Doubling the aspirin dose * • Not indicatedif previous stroke. Caution in patients >75 yo or <60kg. • Indicated if Acute stent thrombosis or at least 2 of the followingriskfactors: • (i) diabetes or overweight(BMI>30); (ii) High on-treatmentplateletreacitivty; (iii) carriage of the 2C19*2 variant

More Related